Literature DB >> 27222429

Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.

Bo Shen1, Yingjie Jiang1, Yuan-Ran Chen2, Hui-Cong Zheng1, Wei Zeng1, Yu-Yuan Li1, Aoxian Yin1, Yuqiang Nie1.   

Abstract

As a member of the tissue inhibitor of metallo-proteinases (TIMP) family, it has been reported that TIMP-3 is involved in human cancer development. However, the function of TIMP-3 in hepatocellular carcinoma (HCC) development is unclear. We aimed to determine the biological role of TIMP-3 in HCC by evaluating the effects of its methylation status and expression on HCC cell function. TIMP-3 expression in HCC tissues was visibly analyzed by immunohistochemistry. Methylation of the TIMP-3 promoter was evaluated by methylation-specific PCR. Effects of TIMP-3 on HCC cell growth, apoptosis, migration, and invasion were examined by transfecting the TIMP-3-expressing plasmid, pCMV6. TIMP-3 was expressed in non-tumorous live tissue, but silenced or downregulated in 60% of HCC cases (P<0.05). Reduced protein expression of TIMP-3 was associated with reduced tumor differentiation (P=0.003) and increased metastatic activity (P=0.005) in HCC cell lines. Promoter methylation contributed to the TIMP-3 inactivation. Overexpression of TIMP-3 in HCC cell lines suppressed cell proliferation, induced apoptosis, and inhibited migration and invasion in vitro. TIMP-3 expression is suppressed by promoter methylation in HCC. This inhibitory protein acts as a functional tumor suppressor by inhibiting HCC cell proliferation, invasion, and migration and by inducing apoptosis and cell cycle arrest at the G2/M phase.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27222429     DOI: 10.3892/or.2016.4818

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Remifentanil reduces the proliferation, migration and invasion of HCC cells via lncRNA NBR2/miR-650/TIMP3 axis.

Authors:  Wei Liang; Jinyuan Ke
Journal:  Int J Exp Pathol       Date:  2022-02-13       Impact factor: 1.925

Review 2.  The Emerging Roles of circSMARCA5 in Cancer.

Authors:  Haoyu Qin; Renhua Wan
Journal:  J Oncol       Date:  2022-06-07       Impact factor: 4.501

3.  Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.

Authors:  Viviana Casagrande; Alessandro Mauriello; Simone Bischetti; Maria Mavilio; Massimo Federici; Rossella Menghini
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

Review 4.  Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis.

Authors:  Jiaxing He; Weiqin Chang; Chunyang Feng; Manhua Cui; Tianmin Xu
Journal:  Int J Genomics       Date:  2018-03-27       Impact factor: 2.326

Review 5.  The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Authors:  Ruth M Escalona; Emily Chan; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

Review 6.  The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma.

Authors:  Fang Wang; Greg Malnassy; Wei Qiu
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

7.  Exosomal miR-452-5p Induce M2 Macrophage Polarization to Accelerate Hepatocellular Carcinoma Progression by Targeting TIMP3.

Authors:  Hu Zongqiang; Chen Jiapeng; Zhao Yingpeng; Yan Chuntao; Wang Yiting; Zhu Jiashun; Li Li
Journal:  J Immunol Res       Date:  2022-09-16       Impact factor: 4.493

8.  TIMP3 attenuates cerebral ischemia/reperfusion-induced apoptosis and oxidative stress in neurocytes by regulating the AKT pathway.

Authors:  Linglei Meng; Yongting Zhang; Demao Li; Xinfang Shang; Xuejia Hao; Xin Chen; Fengxiao Gao
Journal:  Exp Ther Med       Date:  2021-07-08       Impact factor: 2.447

9.  Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases.

Authors:  Libo Sun; Kang Li; Guihai Liu; Yuan Xu; Aiying Zhang; Dongdong Lin; Haitao Zhang; Xiaofei Zhao; Boxun Jin; Ning Li; Yonghong Zhang
Journal:  Cancer Med       Date:  2018-09-27       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.